益气解毒方联合表皮生长因子受体络氨酸激酶抑制剂靶向治疗气阴两虚型非小细胞性肺癌患者的疗效观察  

Study on the Therapeutic Effect of Yiqijiedu Formula Combined with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Treatment on Patients with Non-small Cell Lung Cancer with Deficiency of Both Qi and Yin

作　　者：张楠 胡燕 范建 邓治平[1] ZHANG Nan;HU Yan;FAN Jian;DENG Zhi-ping(Department of Respiratory and Critical Care Medicine,Zigong First People Hospital,Zigong Sichuan 643000)

机构地区：[1]自贡市第一人民医院呼吸与危重症医学科,四川自贡643000

出　　处：《世界中西医结合杂志》2023年第2期401-405,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：四川省医学科研课题计划(S19046)。

摘　　要：目的探究益气解毒方联合表皮生长因子受体络氨酸激酶抑制剂(Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,EGFR-TKI)靶向治疗对气阴两虚型非小细胞肺癌(Non-small cell lung cancer,NSCLC)患者的疗效。方法选取2018年2月—2021年2月期间在自贡市第一人民医院住院治疗的100例NSCLC患者,按随机数字表法分为对照组和治疗组,每组各50例。对照组患者仅接受EGFR-TKI靶向治疗,治疗组患者接受益气养阴解毒方和EGFR-TKI联合治疗。治疗4周后,观察比较两组患者近期疗效、中医证候疗效、生活质量改善率、不良反应及无进展生存期。结果治疗后治疗组近期疗效总有效率84.0%(42/50)较对照组62.0%(31/50)明显升高,差异有统计学意义(P<0.05)。治疗后治疗组中医证候有效率82.0%(41/50)较对照组60.0%(30/50)明显升高,差异有统计学意义(P<0.05)。治疗后治疗组患者生活质量改善有效率92.0%(46/50)较对对照组74.0%(37/50)明显升高,差异有统计学意义(P<0.05)。治疗期间,两组患者皮疹、腹泻不良反应比较,差异无统计学意义(P>0.05)。治疗后治疗组无进展生存期明显高于对照组,差异有统计学意义(P<0.05)。结论益气解毒方联合EGFR-TKI靶向治疗临床疗效较好,可减少EGFR-TKI的副作用发生,改善临床症状,延长无进展生存期。Objective To explore the therapeutic effect of Yiqijiedu Formula combined with epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TLI)targeted treatment on patients with non-small cell lung cancer(NSCLC)with deficiency of both qi and yin.Methods A total of 100 patients with NSCLC hospitalized in Zigong First People Hospital from February 2018 to February 2021 were divided into the control group and the treatment group by random number table,with 50 cases in each group.The patients in the control group only received EGFR-TLI targeted treatment,while the patients in the treatment group received the combination treatment of Yiqiyangyin Jiedu Formula and EGFR-TLI.After four weeks of treatment,the short-term efficacy,TCM syndrome efficacy,life quality improvement rate,adverse reactions and progression-free survival were compared.Results After treatment,the overall effective rate of short-term efficacy of the treatment was 84.0%(42/50),which was significantly higher than the 62.0%(31/50)of the control group(P<0.05).After treatment,the effective rate of TCM syndrome efficacy of the treatment group was 82.0%(41/50),which was significantly higher than the 60.0%(30/50)of the control group(P<0.05).After treatment,the effective rate of life quality improvement of the treatment group was 92.0%(46/50),which was significantly higher than the 74.0%(37/50)of the control group(P<0.05).During treatment,there was no statistical difference in the adverse reactions of rash and diarrhea between the two groups(P>0.05).After treatment,the progression-free survival in the treatment group was significantly longer than that in the control group(P<0.05).Conclusion Yiqijiedu Formula combined with EGFR-TLI targeted treatment has a good clinical effect,and it can reduce the occurrence of side effects of EGFR-TLI,improve clinical symptoms,and prolong progression-free survival.

关 键 词：非小细胞性肺癌 益气解毒方 EGFR-TLI 气阴两虚型 

分 类 号：R734.2[医药卫生—肿瘤]